Zydus Cadila plans to withdraw from drug discovery alliance with Eli Lilly
Indian pharmaceutical company, Zydus Cadila is planning to withdraw from its collaboration with Eli Lilly that involved joint drug discovery for cardiovascular diseases.
Both the companies entered into the drug discovery alliance in March 2009.
It is believed that Zydus Cadila and Eli Lilly are faced with issues concerning differences in strategy and rising costs of research.
Zydus Cadila was entitled for a payment of about $300m depending on the achievement of significant milestones, under the collaboration.
Related Insight
Suppliers Directory
ChemAxon - Solutions for Cheminformatics
ChemAxon provides software applications and toolkits for life science researchers and IT developers to enable structure visualization and management, property predictions and calculations, virtual synthesis, screening, clustering and drug design. We support all popular operating systems and web browsers and have nodes and interfaces for other integration routes like web services, SharePoint and workflow platforms such as Pipeline Pilot and KNIME.
Drug Research > Drug Discovery & Development > Suppliers
MPI Research - Drug Safety, Discovery, and Bioanalytical and Analytical Services
MPI Research, with global headquarters in Mattawan, Michigan, provides discovery, safety evaluation, bioanalytical, and analytical services to the biopharmaceutical, medical device, animal health, and chemical industries.
Drug Research > Drug Discovery & Development > Suppliers
Bioceros - Pre-Clinical Development of Monoclonal Antibodies and Generation of GMP-Ready Proteins
Bioceros is one of Europe's premier providers of services in pre-clinical development of monoclonal antibodies and generation of GMP-ready protein producing cell lines.
Drug Research > Drug Discovery & Development > Suppliers
Investigator Location Services - Instant Access to Experienced Clinical Investigators
Investigator Location Services, Inc. (ILS), is the largest study broker with instant access to over 20,000 experienced clinical research investigators in the US and Canada in all medical specialties and practice settings. Our site provides a center for all clinical research and clinical trial personnel solutions.
Drug Research > Drug Discovery & Development > Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Discovery & Development Intelligence
Biotechnology Solution Brief
Published by Brainloop
Drug Research > Drug Discovery & Development > White Papers
Oncology and Clinical Trials in the 21st Century
Published by BioClinica
Drug Research > Drug Discovery & Development > White Papers
GA-Map™ Technology
Published by Genetic Analysis
Drug Research > Drug Discovery & Development > White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.